4D Molecular Therapeutics, Inc. (FDMT)
| Market Cap | 484.48M |
| Revenue (ttm) | 85.21M |
| Net Income (ttm) | -140.11M |
| Shares Out | 51.05M |
| EPS (ttm) | -2.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 437,124 |
| Open | 9.65 |
| Previous Close | 9.45 |
| Day's Range | 9.40 - 9.65 |
| 52-Week Range | 3.00 - 12.34 |
| Beta | 2.93 |
| Analysts | Strong Buy |
| Price Target | 31.71 (+234.14%) |
| Earnings Date | May 8, 2026 |
About FDMT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is... [Read more]
Financial Performance
In 2025, 4D Molecular Therapeutics's revenue was $85.21 million, an increase of 230194.59% compared to the previous year's $37,000. Losses were -$140.11 million, -12.90% less than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for FDMT stock is "Strong Buy." The 12-month stock price target is $31.71, which is an increase of 234.14% from the latest price.
News
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4DMT to Participate in Upcoming Investor Meetings
EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4D Molecular Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing gene therapies for retinal diseases, with 4D-150 showing strong phase 2 efficacy and safety, and phase 3 trials fully enrolled or on track. Cash runway extends into 2028, and commercial plans include flexible pricing and independent US/EU launches.
4D Molecular Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Lead asset 4D-150 achieved rapid phase III enrollment, reflecting strong unmet need and physician enthusiasm. Commercialization strategies are tailored for U.S., EU, and Asia-Pacific, with broad label expectations and significant pricing flexibility. Cash runway extends into 2028.
4D Molecular Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
4D-150, a gene therapy for wet AMD and DME, is advancing through global phase III trials, showing strong safety and significant reductions in treatment burden. The program is ahead of schedule, with robust clinical data, scalable manufacturing, and a cash runway into 2028.
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected t...
4D Molecular Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing 4D-150, a gene therapy for retinal diseases, with strong safety and efficacy data, regulatory alignment, and a robust financial position. Major milestones include phase 3 trial completions and data readouts through 2027, supported by strategic partnerships.
4DMT Provides Company Update and Anticipated Development Milestones for 2026
EMERYVILLE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4D Molecular Therapeutics Transcript: Study Result
Interim phase I data from the AEROW trial in cystic fibrosis showed that the inhaled gene therapy was well tolerated, achieved durable and targeted CFTR expression, and led to clinically meaningful improvements in lung function and quality of life, especially at the selected phase II dose. LCI is emerging as a sensitive endpoint, and redosing strategies are being refined as the program advances.
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic ...
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4D Molecular Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Long-term data for 4D-150 shows sustained efficacy and safety, with an 80% reduction in treatment burden over two years. Phase III trials are progressing rapidly, and a mass-market pricing strategy is planned. Upcoming CF program data will highlight safety and new efficacy endpoints.
4DMT to Participate in 8th Annual Evercore Healthcare Conference
EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4D Molecular Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Presenters highlighted transformative gene therapies for wet AMD, DME, and cystic fibrosis, with 4D-150 showing up to 92% reduction in injection burden and strong safety. Commercial momentum includes a major Asia-Pacific licensing deal and multiple late-stage trials, with key data readouts expected through 2027.
4DMT Appoints Kristian Humer as Chief Financial Officer
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive...
4DMT to Participate in Jefferies 2025 London Healthcare Conference
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
EMERYVILLE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
4D Molecular Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Gene therapy for cystic fibrosis is advancing rapidly, targeting unmet needs in patients not eligible for modulators. Innovations in vector design, delivery, and manufacturing are improving efficacy, safety, and scalability, while regulatory and commercial strategies are adapting to support broader patient access and combination therapies.
4D Molecular Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Panelists presented late-stage gene therapy programs for major eye diseases, emphasizing durability, safety, and market segmentation as key differentiators. Regulatory flexibility, novel endpoints, and commercial models were discussed, with consensus that multiple innovative therapies will shape a large, heterogeneous market.
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...